{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=7", "query": { "intervention": "DEXAMETHASONE", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1867, "total_pages": 187, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T10:43:53.771Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03412565", "title": "A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2018-04-26", "completion_date": "2024-04-18", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 16, "location_summary": "Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more", "locations": [ { "city": "Southington", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412565" }, { "nct_id": "NCT02874742", "title": "Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 224, "start_date": "2016-08-29", "completion_date": "2022-04-08", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02874742" }, { "nct_id": "NCT07084441", "title": "Comparison of Outcomes of Management of Bowel Obstruction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Adhesive Small Bowel Obstruction" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Supportive Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2026-02-03", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 4, "location_summary": "New York, New York • Seattle, Washington", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07084441" }, { "nct_id": "NCT07728188", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2026-11-30", "completion_date": "2033-02", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 24, "location_summary": "Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07728188" }, { "nct_id": "NCT02030483", "title": "Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-02", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02030483" }, { "nct_id": "NCT02780479", "title": "Steroids in Children Hospitalized With Asthma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma", "Status Asthmaticus", "Wheezes" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 6, "start_date": "2017-03-20", "completion_date": "2017-08-29", "has_results": false, "last_update_posted_date": "2019-06-21", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780479" }, { "nct_id": "NCT00104403", "title": "Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nausea and Vomiting, Chemotherapy-Induced", "Chemotherapy-Induced Nausea and Vomiting" ], "interventions": [ { "name": "GW679769", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ondansetron Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 722, "start_date": "2004-12", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2015-04-16", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Corona", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104403" }, { "nct_id": "NCT00923273", "title": "Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "FDG-PET", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Vitamin B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Folic acid tablets", "type": "DIETARY_SUPPLEMENT" }, { "name": "Dexamethasone tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2008-02-29", "completion_date": "2013-03-10", "has_results": true, "last_update_posted_date": "2019-11-26", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923273" }, { "nct_id": "NCT01665794", "title": "Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2012-08-13", "completion_date": "2025-11-14", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 4, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01665794" }, { "nct_id": "NCT00940524", "title": "Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Dasatinib, Mitoxantrone, Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2009-07", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-04-10", "last_synced_at": "2026-10-23T10:43:53.771Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00940524" } ] }